FDA Supplement Label Requirements: 5 Mistakes Brands Make

There are three kinds of people who arrive at this page, and none of them are browsing.

You have a label already printed and the containers are somewhere on the water. Or a marketplace has asked you for a document you do not recognise and quietly suppressed the listing. Or the letter has already come, with a warning letter number in the top right corner and a response date at the bottom.

Same root cause almost every time. Not the formula. The sentences wrapped around it.

The short answer, for anyone who needs it in the first thirty seconds: five failures account for most of it. A disclaimer that is missing, paraphrased or in the wrong place. A claim that quietly crossed into disease. A Supplement Facts panel that does not meet 21 CFR 101.36. No domestic address or phone number. And a product name that is, by itself, a claim.

Under DSHEA, nobody at the FDA reads your label before you sell. That is the bargain: no pre-market approval, in exchange for following the labeling rules exactly as written. Break one and the product becomes misbranded — which in law is not the product you thought you were shipping.

I spent seventeen years reading labels other people wrote. Ampoules, powders, imported boxes with an English sticker pasted over the Chinese. Hospital pharmacy teaches you one reflex that never leaves: every line on a label should point back to something you can name. A batch number. A monograph. A regulation. When I read a supplement label now, I read it the same way.

This is the long version of what that reflex catches. It is regulatory reading, not legal advice, and it is written for people whose product is already real.

What has to be on the label, before we get to the mistakes

A US dietary supplement label carries six things, and they sit on different panels for different reasons.

The statement of identity. On the principal display panel, in bold, sized in reasonable relation to the most prominent print on that panel. And it has to identify the product as a dietary supplement — 21 CFR 101.3(g) allows you to drop “dietary” only if you replace it with the ingredient name or a descriptive term, e.g. “calcium supplement,” “herbal supplement with vitamins.” A brand name alone is not an identity statement. This trips up more Chinese-language brands than any other clause, because the brand name is usually the only thing translated with care.

Net quantity of contents. How much is in the package, in US customary units, on the display panel — 21 CFR 101.7.

The Supplement Facts panel. Serving size, servings per container, every dietary ingredient by name and quantity, percent Daily Value where one exists, and a symbol pointing to “Daily Value not established” where one does not. 21 CFR 101.36 governs the whole panel, down to the order of the vitamins.

Name and place of business. 21 CFR 101.5(a) and (d): the name of the manufacturer, packer or distributor, plus street address, city, state and ZIP. If the name on the label is not the manufacturer, 101.5(c) requires a qualifier — “Manufactured for,” “Distributed by,” or words to that effect. An email address is not a place of business.

A domestic address or domestic phone number. Section 403(y) of the FD&C Act (21 U.S.C. 343(y)) requires a US address or US phone number through which the responsible person can receive a serious adverse event report. Without it the supplement is misbranded. For an overseas brand this is the clause that hurts: a Hong Kong or Shenzhen address, however legitimate, does not satisfy it.

The disclaimer, if you make a structure/function claim. Which brings us to the mistakes.

If you want the wider picture of how supplement safety works in the US — what gets recalled, what gets seized, what the red flags look like from the consumer side — I wrote that up separately in the complete guide to dietary supplement safety. This article stays on labeling.

The five mistakes, and what each one actually violates

I have ordered these by how often they appear, not by how serious they are. The fifth one is the most expensive and the least discussed.

Mistake 1 — The disclaimer is missing, rewritten, or in the wrong place

A structure/function claim is the only claim about what the product does that a supplement can make without FDA authorisation — nutrient content claims are about how much of a nutrient is present, and health claims need the agency’s sign-off first. “Supports immune function.” “Helps maintain healthy bones.” In exchange, three things are required: you hold substantiation that the statement is truthful and not misleading, you carry the disclaimer, and you notify the FDA within 30 days of first marketing.

The disclaimer wording is fixed and may not be modified — 21 CFR 101.93(c)(1) for a single statement, (c)(2) for the plural version. It must be in boldface, in type no smaller than one-sixteenth of an inch (101.93(e)). And under 101.93(d) it goes either immediately adjacent to the claim with no intervening material, or elsewhere on the same panel or page inside a box, linked to the claim by a matching symbol.

Where brands break this: they place the disclaimer at the bottom of the back panel while the claim sits on a website, an insert, or a different panel. “Same panel or page” is not a suggestion. Nor is “this product is not intended to treat any disease” — a paraphrase is not the disclaimer, it is the absence of one.

Mistake 2 — The claim crossed the disease line

21 CFR 101.93(g)(1) defines a disease as damage to an organ, part, structure or system such that it does not function properly, or a state of health leading to that — hypertension being the example given. Deficiency diseases like scurvy and pellagra are carved out.

The line is easier to see in the FDA’s own examples than in the regulation. “Reduces cholesterol” is a disease claim, because cholesterol is tied to cardiovascular disease and its treatment. “Maintains cholesterol levels that are already within the normal range” is a structure/function claim. “Supports the body’s ability to resist infection” is a disease claim. “Supports the immune system” is not, because the immune system has both a structure/function role and a disease-fighting one, so the general statement does not focus the product on disease.

Note what does the work: already within the normal range. Six words, and the claim moves from illegal to legal. Words like support, maintain, promote and regulate are not automatically disease claims — context decides. Restore is more dangerous than maintain, because it implies something was damaged.

Mistake 3 — The Supplement Facts panel does not survive a second reading

21 CFR 101.36(c)(3) requires a proprietary blend to declare the total weight of all the other dietary ingredients, on the same line as the blend name. The constituents go underneath, indented, in descending order by weight — (c)(2). And the blend must carry a symbol that refers to the same symbol at the bottom of the panel, followed by “Daily Value not established” — (b)(3)(iv).

Two failures show up constantly. A blend listed with its ingredients but no total weight, which leaves the panel non-compliant with 101.36(c)(3). And botanicals with no established Daily Value printed without the asterisk and the footnote — turmeric, ashwagandha, most of the shelf. If you have no %DV column, the symbol goes directly after the weight of each such ingredient instead.

The same paragraph of the regulation covers something almost nobody checks: 101.36(d)(1) requires botanicals to be listed by common or usual name and to specify the part of the plant from which the ingredient is derived. “Astragalus” is incomplete. It is “Astragalus root.” I will come back to this, because it matters more for Chinese formulas than for anything else on this list.

Mistake 4 — There is no US address or US phone number

Section 403(y) is short and unforgiving. If the label of a dietary supplement marketed in the United States does not include a domestic address or domestic phone number through which the responsible person may receive a serious adverse event report, the supplement is misbranded. Full stop.

Marketers read this as “put a US distributor’s address on the box,” which is close but not the same thing. The address has to be one where the responsible person can actually receive that report. A virtual office with nobody to answer does not fix the exposure in practice; it relocates it. Three questions decide whether an address is usable: is the place actually operating, will someone sign for an FDA letter delivered there, and is that party willing to be named on the label as the one receiving adverse event reports. Miss any one of them and the address is decoration.

Mistake 5 — The product name is the claim

This is the one that gets missed because it is not a sentence anyone proofreads. Under 21 CFR 101.93(g)(2)(iv), a statement can become a disease claim through the name of the product. The FDA’s own examples include “CarpalHealth” and “CircuCure.” A name carrying a disease name, or the fragment “cure,” can make the whole label a disease claim before a single line of copy is read.

Translate that into real life. A name that has sold for two decades at home walks onto a US label as “Gout Pills” (痛风丸), or “Glucose-Reducing Capsules” (降糖胶囊), or “Rhinitis Clear” (鼻炎清). Each one is a disease claim sitting on the front of the box in the largest type you own, and no amount of careful wording on the back panel repairs it. The images do the same work: a heart symbol, an EKG tracing, a picture of abnormal tissue — all cited by the FDA as implicit disease claims. A picture of a healthy organ is not.

The comparison table

Every row below points to a specific clause or to the FDA’s Small Entity Compliance Guide on Structure/Function Claims (January 2002), which restates the rule in plain language with worked examples. The “should read” column gives the shape of a compliant sentence, not a template to paste — whether a given sentence is compliant depends on your ingredient, your substantiation and your label as a whole.

What the label says	Why it fails	What it should read instead
“This product treats arthritis.”	Direct disease claim. 21 CFR 101.93(g)(2)(i) — a statement that claims an effect on a specific disease or class of diseases. The FDA’s guide uses “reduces the pain and stiffness associated with arthritis” as its example of an implied disease claim.	“Supports joint comfort.” Structure/function, so it needs the 101.93(c) disclaimer in bold at no less than 1/16 inch, and the 30-day notification under 101.93(a)(1).
“Reduces cholesterol.”	Implied disease claim. Small Entity Compliance Guide, Criterion 2: reducing cholesterol is so tightly tied to cardiovascular disease and its treatment that any such statement is an implied disease claim.	“Maintains cholesterol levels that are already within the normal range.” This is the FDA’s own example of an acceptable structure/function claim.
“Supports the body’s ability to resist infection.”	Disease claim, and the FDA says so explicitly. Criterion 8: fighting disease or enhancing the body’s disease-fighting function is a disease claim.	“Supports the immune system.” Same guide, same criterion: general enough not to focus the product on disease.
“Proprietary Blend” followed by the ingredient list, with no total weight and no footnote.	21 CFR 101.36(c)(3) requires the total weight of the blend’s other dietary ingredients on the same line as the blend name; (b)(3)(iv) requires the symbol and the “Daily Value not established” footnote.	“Proprietary Blend 1,200 mg ” on one line, constituents indented beneath in descending order by weight per 101.36(c)(2), and “ Daily Value not established” at the foot of the panel.
“Arthritis Formula” or “CircuCure” as the product name.	Implicit disease claim through the name. 21 CFR 101.93(g)(2)(iv)(A); the FDA’s examples are “Arthritis Formula,” “CarpalHealth,” “CircuCure.” Separate failure: 101.3(g) requires the identity statement to identify the product as a dietary supplement.	A neutral brand name, with the identity line carrying “dietary supplement” (or “herbal supplement”), and the benefit moved into a compliant structure/function sentence on the information panel.

One more that belongs in the table but has no good sentence-level fix: a label with no domestic address or phone number fails 403(y) regardless of how well everything else is written.

If you want to see how the same claims logic plays out from the consumer’s side — the patterns that mark an advertisement as untrustworthy before you check a single ingredient — I broke eight of them down here.

Most labels fail on one of those five rows, and the seller usually finds out from a marketplace email rather than from a lawyer. If you would rather hear about the next rule change before it arrives as a complaint, leave an email here.

Chinese herbal formulas: the extra layer that catches overseas brands

Everything above applies to a bottle of magnesium capsules and to a box of Xiao Qing Long Tang (小青龙汤) equally. But herbal products carry additional obligations, and traditional Chinese formulas sit on top of several of them at once. Four things, in order of how badly they end.

The plant part is part of the name. 21 CFR 101.36(d)(1) requires the common or usual name and the part of the plant used. Root, rhizome, leaf, seed, bark, fruit — the part is not decorative detail, it is how an ingredient is identified. For formulas built from classical texts this is also where translation goes wrong: gui zhi (桂枝) and rou gui (肉桂) are the same plant, different parts, different pharmacopoeial entries, and “cinnamon” flattens both.

A new dietary ingredient needs 75 days’ notice. Under 21 CFR 190.6, if a supplement contains a dietary ingredient that was not present in the food supply as an article used for food in a chemically unaltered form before 15 October 1994, the manufacturer or distributor must notify the FDA at least 75 days before introducing it into interstate commerce. The notification has to name the ingredient and, for any herb or botanical, give the Latin binomial including the author citation — 190.6(b)(2). It goes through FDA’s new dietary ingredient notification pathway, not to a general inbox. For many classical Chinese ingredients, that pre-1994 US marketing history is not documented anywhere you can point to. A formula that has been sold in China for four hundred years is still, in US terms, an ingredient whose pre-1994 US marketing history needs to be established. This is the quietest failure mode on the list, because nothing on the label looks wrong.

Aristolochic acid is a detention, not a warning. Import Alert 54-10 authorises detention without physical examination of bulk or finished dietary supplements containing aristolochic acid. The alert names Aristolochia species under their Chinese names — guan mu tong (关木通), guang fang ji (广防己), ma dou ling (马兜铃), tian xian teng (天仙藤), qing mu xiang (青木香) — and also lists Asarum species (xi xin, 细辛), Cocculus and Thottea, because the problem is not only intentional use. It is misidentification: one plant substituted for another, or a formula name mistranslated. The alert also flags a set of finished Chinese formulas that commonly use one of these botanicals, including Xiao Qing Long Tang (小青龙汤), Dang Gui Si Ni Tang (当归四逆汤), Du Huo Ji Sheng Tang (独活寄生汤), Chuan Xiong Cha Tiao Wan (川芎茶调丸), Da Qin Jiao Tang (大秦艽汤) and Jiu Wei Qiang Huo Tang (九味羌活汤). For a supplement, release from detention requires an LC-MS analysis showing the product is free of aristolochic acid. That is a laboratory result, not an explanation.

Ephedrine alkaloids are adulterated by regulation. 21 CFR 119.1 states that dietary supplements containing ephedrine alkaloids present an unreasonable risk of illness or injury and are adulterated under section 402(f)(1)(A) of the Act. This is not a labeling problem you can word your way out of. Ma huang (麻黄) is an ephedrine-alkaloid botanical, which puts it inside that sentence, and it sits in a number of classical formulas by function.

The pattern across all four: Chinese herbal formulas fail in the US less often because a marketer wrote something aggressive, and more often because a correct Chinese label was translated into an incomplete English one. The label was never wrong in Chinese. It became wrong in the crossing.

I wrote about the wider version of that crossing — how TCM entered the American market and what it had to leave behind on the way — in this piece on Chinese medicine in America. And for a worked example of what an FDA safety alert actually means when it lands on a botanical product, the tejocote case is the clearest one I have covered.

The checklist I would run before the printer starts

Print this and go down it with the actual artwork in front of you, not with the design file.

Panel by panel

Identity statement on the display panel, in bold, containing “dietary supplement” or an approved substitute term.
Net quantity in US customary units, on the display panel.
Supplement Facts: serving size, servings per container, every ingredient named and quantified.
%DV present for every nutrient with an established Daily Value.
Asterisk and “Daily Value not established” for every ingredient without one — and for any proprietary blend, per 101.36(b)(3)(iv) and (c)(3).
Proprietary blends: total weight on the same line as the blend name, constituents indented and in descending order by weight.
Botanical ingredients: common name plus the plant part.
Name and place of business with street address, city, state, ZIP — and a “Manufactured for” or “Distributed by” qualifier if the named firm is not the manufacturer.
A domestic US address or US phone number for serious adverse event reports.

Claim by claim

Every sentence that describes what the product does, sorted into structure/function versus disease. Anything naming a disease, or using treat, cure, prevent, diagnose or mitigate, comes out.
Nothing softened into a near-synonym. “Supports healthy blood sugar” is a different claim from “controls blood sugar,” and only one of them survives.
Disclaimer present, verbatim, bold, at least 1/16 inch, adjacent to the claim or boxed on the same panel with a matching symbol.
Product name checked, in English, against the disease-claim criteria — including anything that reads as “cure,” “formula for [disease],” or a symptom in the largest type on the box.
Images checked: heart symbols, EKG tracings, pictures of diseased tissue.
Substantiation on file for every claim, dated before the claim went live.
The 30-day notification to the FDA prepared, because the clock starts at first marketing and does not pause while you decide.

Herbal only

Latin binomial recorded for every botanical, with the plant part.
Pre-1994 US market history documented for every ingredient, or a 75-day new dietary ingredient notification on file.
Supplier COA includes aristolochic acid testing by LC-MS for anything in the Aristolochiaceae family or at risk of substitution — xi xin, mu tong, fang ji, qing mu xiang.
No ephedrine alkaloid ingredients.

Twenty items. It takes about forty minutes with a printed label and a pen, and it is the cheapest forty minutes in the whole launch.

I have put this checklist into a printable PDF with the clause reference next to each line, so it can be handed to a designer or a factory without the rest of this article. Ask for it at linkai1991@outlook.com and I will send it back — no list, no sequence, just the file.

One more thing, if labeling is what you do all day

I don’t publish on a schedule, and I am not going to pretend otherwise. What I do send is the clause-level news that changes a label: an import alert that adds a botanical, a warning letter that reveals a pattern, a rule that gets revised after fifteen years of sitting still. Written the way this article is written, with the citation in the sentence, so you can check me. Nothing at all when there is nothing to say.

If you would rather have someone read the label

I read labels for a living before I read them for clients — seventeen years in hospital pharmacy, where a mislabeled ampoule is not a compliance issue but an event. What I do now is narrower and more specific: I read supplement labels and the claims around them, line by line, against the clauses above, and I tell you which lines will not survive and what to write instead. Not a certification, and no promise about how any regulator will rule. A written read of what you have, citing what each problem violates.

If your label is already at the printer, that is exactly the right time to ask.

Written in Chinese, brought into English with AI — the reading, the judgment and the seventeen years are mine. Regulatory summary only, current as of October 2026; verify against the eCFR and the FDA’s current guidance before you print. Not legal advice.

ubscribe for free — and I’ll send you the Cold & Flu Medicine Ingredient Chart.